Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)

Monday, 10 May 2021, 15:15:00
ENGLEWOOD, Colo. , May 10, 2021 /PRNewswire/ — Ampio Pharmaceuticals (NYSE: AMPE ), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board (IRB) approval to commence enrollment in its AP-018 Phase I study using inhaled Ampion™ with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long (or long-haul) COVID, or Post-Acute Sequelae of SARS-CoV-2. “This trial is both needed and exciting in that it addresses a major current and expected ongoing unmet medical need among the estimated 3 to 10 million individuals currently suffering from long COVID ,” said Michael Macaluso , President and CEO of Ampio. ” A significant percentage of patients who have contracted COVID-19 over the past year – even those with mild or asymptomatic cases – continue to suffer debilitating effects long after there is no detectable virus in their system.
— Benzinga

EXCLUSIVE: Ampio Pharmaceuticals Approved For Clinical Study Of Lead Drug In Long-Term Respiratory COVID-19 Symptoms

Monday, 10 May 2021, 14:45:07
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ), a biopharma developing immunology-based therapies for inflammatory diseases, announced Monday it has received approval to initiate a clinical study of its lead asset for long COVID-19 treatment. Ampion's COVID-19 Study: Englewood, Colorado-based Ampio said an investigational review board has approved the initiation of a Phase 1 study, dubbed AP-018, of its inhaled Ampion in patients exhibiting prolonged respiratory COVID-19 symptoms. This condition is called long/long-haul COVID, or post-acute sequelae of SARS-CoV-2, the virus that causes COVID-19 disease. The Need For Long COVID-19 Treatment: With about 3 to 10 million individuals suffering from long COVID-19, this trial assumes importance … Full story available on Benzinga.com
— Benzinga

The Week In Cannabis: The New Tilray, Jazz-GW Pharma, Earnings, M&A, And More

Friday, 7 May 2021, 23:36:03
This was an eventful week for the cannabis industry. On Monday, Tilray, Inc. (NASDAQ: TLRY ) and Aphria, Inc. (NASDAQ: APHA ) closed their merger after months of negotiations, creating a company with a combined market cap of $3.3 billion. Benzinga spoke with Irwin Simon, CEO of the new combined company. Check out the video below: Following the merger, Jefferies upgraded the rating for Tilray from Underperform to Buy, while raising the price target from $4.77 to $23. Jazz Pharmaceuticals (NASDAQ: JAZZ ) finalized its acquisition of GW Pharmaceuticals plc. (NASDAQ: GWPH ), the producer of the FDA‑approved prescription cannabidiol drug Epidiolex, for $7.2 billion or $6.7 billion net of GW Pharma's cash. Meanwhile, Ascend Wellness Holdings (CSE: AAWH) started trading on the Canadian Securities exchange following a raise of approximately $80 million through an initial public offering of roughly 10 million shares of its Class A common stock at $8 per share. Benzinga Cannabis’ content is now available in Spanish on El Planteo .
— Benzinga

Tilray Stock Is Getting Squeezed Between 2 Key Levels

Friday, 7 May 2021, 22:06:16
Tilray Inc. (NASDAQ: TLRY ) shares were trading higher Friday after a Jefferies analyst double upgraded the stock. The stock was double upgraded from Underperform to Buy and the price target was raised from $4.77 to $23. Tilray recently closed a merger with Aphria Inc. (NASDAQ: APHA ). Click here to read more about why Tilray is moving. Tilray was up 14.7% at $16.23 ahead of the market close Friday. Tilray Daily Chart Analysis The stock is getting squeezed between a previous support and a potential resistance line. The stock may see a strong move in the upcoming weeks. The stock is trading below the 50-day moving average (green) and above the 200-day moving average (blue), indicating the stock is likely trading in a period of consolidation. The … Full story available on Benzinga.com
— Benzinga

Tilray Jumps; Jefferies Double Upgrades on Link With Aphria – TheStreet

Friday, 7 May 2021, 14:51:12
Tilray was upgraded to buy from underperform at Jefferies, which sees ‘a perfect match' in its combination with Aphria.
— The Street